Biocon wins 10-year Brazil PDP contract for pertuzumab supply
Biocon announced a consortium agreement with Bahiafarma and Bionovis to supply pertuzumab under Brazil's 10-year PDP, receiving 100% allocation that covers about 70% of the country's public healthcare demand for the HER2-positive breast cancer therapy. The arrangement includes milestone payments and a revenue share while production is phased to localise in Brazil over the mid to long term. The deal fits Biocon's partnership-led strategy, adds long-term revenue visibility as the company works to deleverage, and complements a biosimilars portfolio of 12 commercialised products and 20+ assets in development.
Biocon secures exclusive 10-year access to about 70% of Brazil pertuzumab demand
Context
Brazil has used PDPs to bring local manufacturing for costly biologics. The country wanted to reduce import costs for pertuzumab. Next, the product will be phased for local production and revenue will flow over ten years.
The full analysis
19 dimensions on this story — world impact, market read, and what happens next.
- Full ContextLocked
- Affected SectorsLocked
- Stock ImpactLocked
- Economic IndicatorLocked
- Investor RelevanceLocked
- Professional RelevanceLocked
- Watch PointsLocked
- Probability of ChangeLocked
- Debate PointsLocked
- Prerequisite KnowledgeLocked
- Follow-up QuestionsLocked
- Pros & ConsLocked